Atai Life Sciences N.V. (FRA:9VC)

Germany flag Germany · Delayed Price · Currency is EUR
5.70
+0.36 (6.83%)
Last updated: Oct 21, 2025, 3:00 PM CET
6.83%
Market Cap1.08B
Revenue (ttm)1.97M
Net Income (ttm)-101.67M
Shares Outn/a
EPS (ttm)-0.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1
Average Volume6,448
Open5.26
Previous Close5.33
Day's Range5.26 - 5.88
52-Week Range0.96 - 5.98
Betan/a
RSI63.17
Earnings DateNov 14, 2025

About Atai Life Sciences

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with sc... [Read more]

Industry Pharmaceutical Preparations
Founded 2018
Employees 54
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 9VC
Full Company Profile

Financial Performance

In 2024, Atai Life Sciences's revenue was $308,000, a decrease of -1.91% compared to the previous year's $314,000. Losses were -$149.27 million, 271.1% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.